Stability and biosafety of human epidermal stem cell for wound repair: preclinical evaluation

Author:

Zhao Xiaohong,Li Xue,Wang Ying,Guo Yicheng,Huang Yong,Lv Dalun,Lei Mingxing,Yu Shicang,Luo Gaoxing,Zhan RixingORCID

Abstract

Abstract Background Cell therapy is a key technology to prevent sacrificing normal skin. Although some studies have shown the promise of human epidermal stem cells (EpiSCs), the efficacy, biosafety and quality control of EpiSC therapy have not been systematically reported. Methods The biosafety, stemness maintenance and wound repair of EpiSC were systematically verified by in vitro and in vivo experiments. EpiSC were prepared from the foreskin using a collagen type IV rapid adherence method. The EpiSCs were identified by flow cytometry, immunofluorescence staining and cell morphology. The well-growing passage 1 (P1) EpiSCs were used to determine the proliferation curve (counting method). EpiSC clone formation assay was performed by Giemsa staining. Nude mice were used to prepare a full-thickness skin defect wound model to detect the repair effect of EpiSCs. The biosafety of EpiSCs was double tested in vitro and in vivo. Results The results showed that the expression of specific markers and clone formation efficiency was stable when passage 1 (P1) to P8 cells were cultured, and the stemness rate of P8 cells was close to 85.1%. EpiSCs were expanded in vitro for 25 days, the number of cells reached 2.5 × 108, and the transplantable area was approximately 75% of the total body surface area (TBSA). At 45 days, the total number of cells was approximately 30 billion, and the transplantable area was approximately the size of a volleyball court. A nude mouse wound model indicated that EpiSCs could rapidly close a wound. On postinjury day 7, the wound epithelialization rate in the cell transplantation group was significantly higher than that in the NaCl group (P < 0.05). In vitro, cell senescence increased, and telomerase activity decreased in P1 to P8 EpiSCs. In vivo, there were no solid tumors or metastatic tumors after EpiSC (P8) transplantation. In addition, the quality control of cultured cells met the clinical application criteria for cell therapy. Conclusion This preclinical study showed the stability and biosafety of human EpiSC therapy for wound repair. Graphical Abstract

Funder

the National Key R&D Program of China

the Chongqing Talent Program in 2021

the Military Medical High-tech Cultivation Project of Army Medical University

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Biochemistry, Genetics and Molecular Biology (miscellaneous),Molecular Medicine,Medicine (miscellaneous)

Reference42 articles.

1. Aragona M, Blanpain C. Gene therapy: transgenic stem cells replace skin. Nature. 2017;551(7680):306–7.

2. He P, Zhao J, Zhang J, Li B, Gou Z, Gou M, Li X. Bioprinting of skin constructs for wound healing. Burns Trauma. 2018;6:5.

3. Zhang GF, Liu WJ, Wang D, Duan JX, Li XQ. Meta-analysis of clinical effects of microskin grafting and Meek microskin grafting in repairing extensively deep burn wounds. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chin J Burns. 2020;36(7):560–7.

4. Cao SJ, Wang LF, Ba T, Rong ZD, Hu GL, Zhou B, Li Q, Yan ZQ. Transplantation of compound tissue flap of toe to reconstruct the thumb with necrosis caused by electric burns in four patients. Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chin J Burns. 2019;35(10):761–3.

5. Roshangar L, Soleimani Rad J, Kheirjou R, Reza Ranjkesh M, Ferdowsi Khosroshahi A. Skin burns: review of molecular mechanisms and therapeutic approaches. Wounds: Compend Clin Res Pract. 2019;31(12):308–15.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3